Indaptus advances Decoy20 combo trial but faces heavy cash burn, limited Q4 2025 runway

Indaptus Therapeutics, Inc. (NASDAQ: INDP) - Quick take

Short summary: the company is a clinical‑stage biotech advancing its lead candidate Decoy20. Financially it's burning cash while raising capital through a SEPA, private placements and convertible notes; management completed a reverse split and the company cleared Nasdaq minimums following subsequent conversion of the June 2025 notes.

Key facts & figures
* Cash and cash equivalents (June 30, 2025): $6,157,701
* Total assets: $6,839,207; Total current liabilities: $8,512,563; Total stockholders' deficit: $(1,673,356)
* Accumulated deficit: $(70,200,532) (June 30, 2025)
* Net loss - six months ended June 30, 2025: $(9,761,349); three months ended June 30, 2025: $(5,228,919)
* Research & development expense - six months 2025: $4,977,954 (up 50.6% YoY); three months 2025: $2,167,114 (up 26.4% YoY)
* General & administrative - six months 2025: $4,051,368 (down 14.7% YoY)
* Net cash used in operating activities (six months): $(9,065,316)
* Net cash provided by financing activities (six months): $9,436,264
* Convertible notes proceeds (June 2025): $5,714,800; fair value recorded at $6,502,503 (June 30, 2025)
* SEPA (Yorkville): up to $20.0 million commitment; H1 2025 net proceeds under SEPA: ~$1.75 million
* Reverse 1‑for‑28 stock split date: June 26, 2025 (retroactively restated amounts). Shares outstanding reported Aug 12, 2025: 1,106,529.

What's happening inside the company - operational / clinical highlights
* Advancing Decoy20 through Phase 1 (single dose and weekly dosing) and shifted focus to a combination study with BeOne's anti‑PD‑1 (Tislelizumab).
* Dosed first participant in the Combination Study (June 2025); 6 participants enrolled by Aug 2025. Observed CRS events but described as transient and resolved within 24-72 hours.
* cGMP manufacturing of Decoy20 accomplished; company reporting early signs of stable disease in some participants-still early and limited data.
* Management implemented cost reductions in May 2025 (prioritizing Combination Study, salary/board fee adjustments).

Income statement - positives
* R&D spend is increasing meaningfully - a sign of active clinical progression (R&D six‑month spend $4.98M).
* G&A decreased (six months) by ~$0.7M YoY, driven by lower stock‑based comp, payroll and investor relations costs - shows some cost discipline.
* Company is securing financing (private placements, SEPA, convertible notes) to keep programs running into Q4 2025 per management.

Income statement - negatives / risks
* Heavy operating loss and cash burn: $(9.76M) net loss for six months and ~$9.1M cash used in operations in H1 2025 - runway limited.
* R&D is rising (50.6% YoY) without revenue - typical for clinical biotechs but increases financing needs and dilution risk.
* Change in fair value of convertible promissory notes added $(787,703) non‑cash expense, inflating reported loss.
* Stockholders' equity is negative as of June 30, 2025; total current liabilities exceeded current assets - management states "substantial doubt" about going concern without further financing.

Capital structure & recent financing events
* January 2025 private placement: 75,335 shares + warrants; net proceeds ~ $2.0M.
* SEPA with Yorkville (Feb 12, 2025): up to $20M over 36 months; sold 89,902 shares under SEPA in H1 for net ~$1.75M.
* June 2025 convertible notes: principal ~$5.7M, measured at fair value $6.5M (June 30). Notes automatically converted July 27, 2025 into 501,566 shares plus issuance of warrants (1,384,722 July 2025 Warrants) - subsequent conversion removed the notes from liabilities and helped the company meet Nasdaq minimum equity requirements.
* Reverse split 1‑for‑28 (June 26, 2025) restored Nasdaq compliance prior to conversions; outstanding share counts adjusted retroactively in the financials.

Balance‑sheet reality & runway
* Management: believes cash at June 30, 2025 (~$6.16M) funds operations into Q4 2025 under current plan.
* But H1 operating cash burn (~$9.1M) implies management must access additional capital soon; available sources (SEPA, equity or debt) likely to dilute existing holders or be costly.

Bottom line - what to watch
* Clinical readouts / safety signals from the Combination Study and any efficacy signals for Decoy20.
* Timing and magnitude of new financing (SEPA draws, equity or partnerships) - critical to avoid program delays or further dilution.
* Quarterly cash burn trends, conversion/exercise activity (warrants, converted notes), and any change in Nasdaq listing status.
* Management execution on cost reduction and ability to convert early clinical progress into staged financings or collaborations.

Bottom line: Indaptus (NASDAQ: INDP) is progressing clinically and has recent financing activity, but it remains a high‑risk, cash‑hungry clinical‑stage biotech with limited runway and a history of losses. Near‑term financing and clinical safety/early efficacy signals will drive the next inflection points.